CJC-1295
Growth Hormone Secretagogue & IGF-1 Axis Activation
What is CJC-1295?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), engineered from the biologically active 1-29 fragment of the native hormone (a region also shared by sermorelin-like sequences). In laboratory research it is studied as a growth hormone secretagogue: it binds the GHRH receptor on somatotroph cells of the anterior pituitary and, in preclinical models, stimulates the synthesis and pulsatile release of endogenous growth hormone (GH). A feature emphasized in the literature is that, unlike administering recombinant GH directly, GHRH analogs are thought to work with the body's natural feedback loops and preserve pulsatile secretion rather than imposing a constant, artificial hormone level.
Two versions are commonly discussed in research contexts. The 'DAC' variant incorporates a drug affinity complex designed to bind circulating albumin, which preclinical work suggests substantially extends its half-life, while the non-DAC form (often called modified GRF(1-29)) is shorter-acting. Downstream of GH release, animal studies describe elevated insulin-like growth factor 1 (IGF-1) produced largely by the liver — the axis through which many of GH's anabolic and metabolic effects are hypothesized to occur. In research settings CJC-1295 is frequently examined together with ghrelin-mimetic secretagogues such as ipamorelin, because the two act on distinct receptor systems and appear to amplify GH pulses when combined.
It is important to be candid about the evidence base. Much of what is known derives from animal models and early pharmacokinetic work, and rigorous, long-term controlled human efficacy trials are limited. Reported effects on body composition, recovery, sleep, or aging in humans remain largely unverified. CJC-1295 is not approved for human use by major regulatory authorities. This material is provided strictly for research and educational purposes only.
Molecular data
Mechanism of action
In preclinical research, CJC-1295 is associated with the following pathways and targets:
Research highlights
- Binds GHRH receptor to stimulate pulsatile GH secretion
- Elevates IGF-1 levels via liver signaling cascade
- Extended half-life compared to native GHRH
- Commonly stacked with Ipamorelin for synergistic GH release
Frequently asked questions
What is CJC-1295 in research?
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) studied as a growth hormone secretagogue. In preclinical models it binds the GHRH receptor on the pituitary and stimulates the pulsatile release of the body's own growth hormone, which is why it is used as a research tool for exploring the GH/IGF-1 axis.
How does CJC-1295 work?
Research suggests it mimics native GHRH by activating the GHRH receptor on pituitary somatotrophs, prompting synthesis and release of endogenous growth hormone. This in turn is associated in animal studies with downstream increases in liver-produced IGF-1. Because it acts upstream, it is thought to preserve natural pulsatile secretion rather than override it.
What is the difference between CJC-1295 with and without DAC?
The DAC (drug affinity complex) version is designed to bind albumin in the blood, which preclinical work suggests markedly extends its half-life. The non-DAC form, often called modified GRF(1-29), is shorter-acting. The distinction is primarily one of studied duration of activity, not the underlying receptor mechanism.
How do CJC-1295 and ipamorelin work together in studies?
The two are frequently paired in research because they act on different receptors — CJC-1295 on the GHRH receptor and ipamorelin on the ghrelin/GHS-R receptor. Studies suggest that combining a GHRH signal with a ghrelin-receptor signal can produce a larger, synergistic GH pulse than either compound alone. These are laboratory observations, not validated human protocols.
Is CJC-1295 approved for human use?
No. CJC-1295 is not approved as a medicine by major regulatory authorities, and controlled human efficacy data are limited. It is sold and studied strictly as a research material, and nothing here should be taken as medical advice or an endorsement of human use.
Source CJC-1295 at Purgo Labs
≥99% purity, third-party COA verification, and same-day fulfillment.
Shop CJC-1295 at Purgo Labs ↗Related compounds
For research and educational purposes only. CJC-1295 is not approved for human use by any regulatory authority, and nothing on this page constitutes medical advice, diagnosis, or treatment. Research findings referenced here are predominantly preclinical.